Table 1.
Characteristics of 773 persons living with HIV enrolled in a NIDA-funded cohort (and 1286 surveys completed by those persons) who completed 1 or 2 surveys about their experiences during the COVID-19 pandemic, 11 May 2020–15 February 2021.
| Observations | Persons | |
|---|---|---|
| N = 1286 (%) | N = 773 (%) | |
| Agea | 51 (37, 58) | 50 (35, 57) |
| Male sex | 943 (73) | 576 (75) |
| Race/ethnicity | ||
| Black, non-Hispanic | 883 (69) | 530 (69) |
| White, non-Hispanic | 117 (9) | 68 (9) |
| Hispanic | 238 (19) | 142 (18) |
| Other, non-Hispanic | 48 (4) | 33 (4) |
| Unstable housing | 68 (5) | 45 (6) |
| Employment | ||
| Employed | 237 (18) | 134 (17) |
| Unstable employment | 167 (13) | 113 (15) |
| Unemployed | 882 (69) | 526 (68) |
| Food insecure | 354 (28) | 228 (29) |
| Moderate-to-severe anxiety | 228 (18) | 149 (19) |
| Brief Resiliency Scale | ||
| Low resilience | 198 (15) | 125 (16) |
| Normal resilience | 877 (68) | 522 (68) |
| High resilience | 211 (16) | 126 (16) |
| Interruptions to mental health care | 644 (50) | 415 (54) |
| Recent drug use | ||
| Smoking | 548 (43) | 342 (44) |
| Hazardous alcohol use | 138 (11) | 82 (11) |
| Cocaine | 126 (10) | 78 (10) |
| Opioids | 59 (5) | 40 (5) |
| Cannabis | 463 (36) | 291 (38) |
| Current substance use treatment | 241 (19) | 160 (21) |
| Disruptions to substance use treatment | 167 (69) | 116 (73) |
| Current opioid agonist therapy | 99 (8) | 68 (9) |
| Disruptions to opioid agonist therapy | 26 (26) | 18 (26) |
| ≥ “Much” disruptions of COVID-19 pandemic | 848 (66) | 519 (67) |
| Substantial worry due to the pandemic | 1001 (78) | 592 (77) |
a
Median (Q1, Q3).